NCT02267655View on ClinicalTrials.gov

3 Part Study to Assess Inhaled Nitric Oxide on Functional Pulmonary Imaging in Subj. Pulmonary Hypertension Associated w/ COPD and IPF

PHASE1CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

May 31, 2015

Primary Completion Date

June 30, 2017

Study Completion Date

June 28, 2017

Conditions
Pulmonary HypertensionChronic Obstructive Pulmonary DiseaseIdiopathic Pulmonary Fibrosis
Interventions
DRUG

inhaled Nitric Oxide - 30 mcg/kg IBW/hr

inhaled Nitric Oxide in 30 mcg/kg IBW/hr doses Part 1

DRUG

inhaled Nitric Oxide 5,10,15 mcg/Kg IBW/hr

inhaled inhaled Nitric Oxide 5,10,15 mcg/Kg IBW/hr dose titration

DRUG

inhaled nitric oxide 75 mcg/kg IBW/hr

inhaled nitric oxide 75 mcg/kg IBW/hr -Part 2b

Trial Locations (1)

2650

Antwerp University Hospital, Edegem

All Listed Sponsors
lead

Bellerophon

INDUSTRY

NCT02267655 - 3 Part Study to Assess Inhaled Nitric Oxide on Functional Pulmonary Imaging in Subj. Pulmonary Hypertension Associated w/ COPD and IPF | Biotech Hunter | Biotech Hunter